Sun Pharmaceutical, the world’s fifth-largest specialty generic company, has reported positive results from two pivotal Phase III clinical trials for its psoriasis candidate tildrakizumab, showing that the targeted biologic therapy delivers “significantly improved” skin clearance. While it will face rising competition, some analysts are predicting strong sales

Sun Pharmaceutical Industries, India’s biggest drug maker by sales, has reported a 30% drop in quarterly net profit from a year earlier, undershooting analysts’ expectations for a third straight trimester and reflecting in part the costs of digesting its merger with Ranbaxy.

Sun Pharmaceutical Industries, India’s biggest drug maker, has announced a 60% slump in quarterly net profit from a year earlier, hit by one-off charges as it integrates troubled former rival Ranbaxy, acquired from Japanese owners Daiichi Sankyo earlier this year. But the generics giant says the “short-term pain” will result in long-term gain.

PhRMA is concerned about the agency giving deference to generic sponsors in patent use code disputes, while GPhA wants a mechanism to challenge refuse-to-receive letters.